CY1124630T1 - Επιλεκτικη αναγωγη αντισωματων τροποποιημενης κυστεϊνης - Google Patents
Επιλεκτικη αναγωγη αντισωματων τροποποιημενης κυστεϊνηςInfo
- Publication number
- CY1124630T1 CY1124630T1 CY20201100821T CY201100821T CY1124630T1 CY 1124630 T1 CY1124630 T1 CY 1124630T1 CY 20201100821 T CY20201100821 T CY 20201100821T CY 201100821 T CY201100821 T CY 201100821T CY 1124630 T1 CY1124630 T1 CY 1124630T1
- Authority
- CY
- Cyprus
- Prior art keywords
- selective reduction
- modified cysteine
- cysteine antibodies
- modified
- antibodies
- Prior art date
Links
- 150000001944 cysteine derivatives Chemical class 0.000 title 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 2
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με μία διεργασία για την επιλεκτική αναγωγή αντισωμάτων τροποποιημένης κυστεΐνης η οποία περιέχει την αντίδραση ενός αντισώματος που περιέχει μια ή περισσότερες τροποποιημένες κυστεΐνες σε θέσεις που επιλέγονται από HC40, HC41, HC42, HC89, HC152, HC153, HC155, HC171, LC40, LC41, LC165, και LC168 με μία ένωση σύμφωνα με τον τύπο (Ι), (ΙΙ), (III), (IV), (V), (VI) ή (VII): (Ι) (II) (III) (IV) (V) (VI) (VII) και με μία διεργασία για την παρασκευή συζευγμάτων αντισωμάτων, συμπεριλαμβανομένων συζευγμάτων αντισώματος φαρμάκου (ADCs).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16155481 | 2016-02-12 | ||
EP16206761 | 2016-12-23 | ||
PCT/EP2017/053157 WO2017137628A1 (en) | 2016-02-12 | 2017-02-13 | Selective reduction of cysteine-engineered antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124630T1 true CY1124630T1 (el) | 2022-03-24 |
Family
ID=58044063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100821T CY1124630T1 (el) | 2016-02-12 | 2020-09-02 | Επιλεκτικη αναγωγη αντισωματων τροποποιημενης κυστεϊνης |
Country Status (14)
Country | Link |
---|---|
US (1) | US10814009B2 (el) |
EP (1) | EP3458100B1 (el) |
AU (1) | AU2017218615B2 (el) |
CA (1) | CA3026139C (el) |
CY (1) | CY1124630T1 (el) |
DK (1) | DK3458100T3 (el) |
ES (1) | ES2818575T3 (el) |
HR (1) | HRP20201183T1 (el) |
HU (1) | HUE050726T2 (el) |
LT (1) | LT3458100T (el) |
PL (1) | PL3458100T3 (el) |
PT (1) | PT3458100T (el) |
SG (1) | SG11201809830WA (el) |
WO (1) | WO2017137628A1 (el) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200010491A (ko) * | 2017-05-23 | 2020-01-30 | 신톤 바이오파머슈티칼즈 비.브이. | 항체-약물 접합체를 제조하기 위한 이중 접합 방법 |
JP7504025B2 (ja) * | 2017-08-04 | 2024-06-21 | アムジエン・インコーポレーテツド | Cys-mabのコンジュゲーション方法 |
US11633492B2 (en) | 2017-11-24 | 2023-04-25 | Byondis B.V. | Process for the synthesis of linker-drug vc-seco-DUBA |
WO2019191630A1 (en) * | 2018-03-29 | 2019-10-03 | Abbvie Inc. | Selective reduction of antibodies |
KR20210125034A (ko) | 2019-02-15 | 2021-10-15 | 우시 바이올로직스 아일랜드 리미티드 | 동질성이 개선된 항체-약물 콘쥬게이트의 제조방법 |
US12109273B2 (en) | 2019-02-15 | 2024-10-08 | Wuxi Xdc Singapore Private Limited | Process for preparing antibody-drug conjugates with improved homogeneity |
AU2021216099A1 (en) | 2020-02-06 | 2022-09-01 | Byondis B.V. | Combination containing a duocarmycin derivative-comprising antibody-drug conjugate and thiosulfate |
IL299184A (en) | 2020-07-06 | 2023-02-01 | Byondis Bv | Anti-folic acid drugs and antibody-conjugated drugs |
JP2024515266A (ja) | 2021-04-08 | 2024-04-08 | ビョンディス・ビー.ブイ. | 抗c-MET抗体及び抗体薬物複合体 |
WO2023275025A1 (en) | 2021-06-28 | 2023-01-05 | Byondis B.V. | Conjugates comprising phosphoantigens and their use in therapy |
EP4457229A1 (en) | 2021-12-30 | 2024-11-06 | Byondis B.V. | Antifolate linker-drugs and antibody-drug conjugates |
WO2023222580A1 (en) | 2022-05-16 | 2023-11-23 | Byondis B.V. | Novel masked antibodies |
WO2024133374A1 (en) | 2022-12-22 | 2024-06-27 | Byondis B.V. | Novel linker drugs comprising phosphoantigens, novel conjugates and their use in therapy |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005286607B2 (en) | 2004-09-23 | 2011-01-27 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
WO2006134174A2 (en) * | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Dimeric and multimeric fviia compound |
LT3108886T (lt) | 2010-04-21 | 2020-08-25 | Syntarga B.V. | Cc-1065 analogų ir bifunkcinių jungtukų konjugatai |
MX2016010295A (es) | 2014-02-11 | 2016-10-17 | Seattle Genetics Inc | Reduccion selectiva de proteinas. |
HUE056023T2 (hu) * | 2014-05-22 | 2022-01-28 | Byondis Bv | Kapcsolt drogok helyspecifikus konjugációja ellenanyagokhoz, és a kapott ADC-k |
-
2017
- 2017-02-13 EP EP17705364.2A patent/EP3458100B1/en active Active
- 2017-02-13 AU AU2017218615A patent/AU2017218615B2/en active Active
- 2017-02-13 ES ES17705364T patent/ES2818575T3/es active Active
- 2017-02-13 PT PT177053642T patent/PT3458100T/pt unknown
- 2017-02-13 LT LTEP17705364.2T patent/LT3458100T/lt unknown
- 2017-02-13 SG SG11201809830WA patent/SG11201809830WA/en unknown
- 2017-02-13 WO PCT/EP2017/053157 patent/WO2017137628A1/en active Application Filing
- 2017-02-13 DK DK17705364.2T patent/DK3458100T3/da active
- 2017-02-13 CA CA3026139A patent/CA3026139C/en active Active
- 2017-02-13 US US16/099,123 patent/US10814009B2/en active Active
- 2017-02-13 PL PL17705364T patent/PL3458100T3/pl unknown
- 2017-02-13 HU HUE17705364A patent/HUE050726T2/hu unknown
-
2020
- 2020-07-29 HR HRP20201183TT patent/HRP20201183T1/hr unknown
- 2020-09-02 CY CY20201100821T patent/CY1124630T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US10814009B2 (en) | 2020-10-27 |
LT3458100T (lt) | 2020-08-25 |
ES2818575T3 (es) | 2021-04-13 |
AU2017218615A1 (en) | 2018-12-13 |
EP3458100A1 (en) | 2019-03-27 |
HRP20201183T1 (hr) | 2021-02-05 |
WO2017137628A1 (en) | 2017-08-17 |
PT3458100T (pt) | 2020-08-05 |
EP3458100B1 (en) | 2020-07-01 |
AU2017218615B2 (en) | 2022-02-10 |
PL3458100T3 (pl) | 2020-11-30 |
DK3458100T3 (da) | 2020-08-03 |
SG11201809830WA (en) | 2018-12-28 |
US20190388552A1 (en) | 2019-12-26 |
HUE050726T2 (hu) | 2021-01-28 |
CA3026139C (en) | 2023-09-12 |
CA3026139A1 (en) | 2017-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124630T1 (el) | Επιλεκτικη αναγωγη αντισωματων τροποποιημενης κυστεϊνης | |
CY1121832T1 (el) | Μονοκλωνικα αντισωματα κατα του παραγοντα αναπτυξεως και διαφοροποιησεως 15(gdf-15) | |
CY1124714T1 (el) | Συζευγματα πυρρολοβενζοδιαζεπινης-αντισωματος | |
CL2018003520A1 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. | |
CY1123358T1 (el) | Υδατικο φαρμακευτικο σκευασμα που περιεχει αντισωμα αντι-pd-1 αβελουμαμπη | |
CY1121573T1 (el) | Συζευγμα αντισωματος anti-her2-φαρμακου | |
CY1120665T1 (el) | Ανθρωποποιημενα αντισωματα anti-cxcr5, παραγωγα αυτων και χρησεις τους | |
CY1123884T1 (el) | Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων | |
CY1117563T1 (el) | Αντισωματα κατα her3 και χρησεις αυτων | |
EA201790359A1 (ru) | Пирролобензодиазепины и их конъюгаты, связанные дисульфидной связью с антителами | |
CY1118761T1 (el) | Αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης 3 (her3) | |
CY1115639T1 (el) | Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου | |
EA201792589A1 (ru) | Антитела против cd123 и конъюгаты указанных антител | |
EA201891040A1 (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
CY1121944T1 (el) | Σταθεροποιημενες πρωτεϊνες για ανοσοποιηση εναντι staphylococcus aureus | |
MX2018015272A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
BR112018075630A2 (pt) | anticorpos anti-cd98 e conjugados de fármaco de anticorpo | |
CL2016000221A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
CY1123231T1 (el) | Ενωσεις τετραϋδροπυριμιδοδιαζεπινης και τετραϋδροπυριδοδιαζεπινης για θεραπεια πονου και καταστασεων σχετικων με τον πονο | |
CY1122025T1 (el) | Βελτιωμενη διεργασια για τη δημιουργια προφαρμακων ντουοκαρμυκινης | |
DK201100184U1 (da) | Method for immunizing an avian species | |
BR112018075651A2 (pt) | anticorpos anti-cd98 e conjugados anticorpo fármaco | |
CY1123514T1 (el) | Κρυσταλλικο 2-φθορο-3-νιτροτολουολιο και διαδικασια για την παρασκευη του | |
EA202192405A1 (ru) | Составы антител против il-36r | |
EA201891586A1 (ru) | Антипролиферативные соединения и их фармацевтические композиции и применения |